#USA #Atlanta #Altesa BioSciences #Vapendavir #Georgia Life Sciences

Altesa BioSciences Honored with Golden Helix Award

Altesa BioSciences, a biopharmaceutical firm situated in Atlanta, has made headlines by receiving the prestigious 2026 Golden Helix Award for the Deal of the Year. This recognition is attributed to their successful $75 million Series B financing, a move that underscores both the investor confidence in the enterprise and the potential it holds to revolutionize treatment for chronic lung conditions such as COPD and asthma.

The awards ceremony took place on August 25, 2026, during the annual Georgia Life Sciences Summit, an event that gathers leaders across the life sciences industry, including investors and innovators. The Deal of the Year accolade highlights transactions that exemplify significant investor faith and the capacity to advance essential therapies in dire need.

Brett Haumann, CEO of Altesa BioSciences, expressed gratitude towards their investors, including the Georgia Research Alliance. He stated, “We are deeply honored to receive this accolade from Georgia Life Sciences, and grateful to our investors whose confidence has enabled Altesa to continue advancing the development of vapendavir.”

The Impact of Series B Financing

The Series B financing round was not only notable for its substantial amount but also for its oversubscription, reflecting robust investor interest in the company’s leading candidate, vapendavir. This funding round was spearheaded by Forbion, with contributions from recognizably serious names in the healthcare industry like Sanofi, alongside existing partners such as Medicxi and Atlantic Partners. The capital raised will propel the ongoing clinical trials for vapendavir, which are pivotal to combating chronic pulmonary diseases.

As asserted by Connor Seabrook, Managing Director of the Georgia Research Alliance Venture Fund, the impressive trajectory of Altesa BioSciences demonstrates the strength and capability of their team, which is backed by a remarkable track record of advancing significant treatments, including their work on the early COVID-19 therapy, molnupiravir.

Vapendavir: A Promising Solution

Vapendavir is currently being developed as an oral medication designed to treat patients suffering from COPD, particularly those impacted by rhinovirus infections. Testing has shown that it can not only alleviate symptoms but also minimize the duration of illness and enhance lung function. By targeting the common viral infections that exacerbate COPD, vapendavir holds the potential to significantly enhance the quality of life for its users and reduce healthcare expenses associated with emergency interventions.

In light of the upcoming CARDINAL clinical trial, a Phase 2b multinational study, Altesa is gearing up to gather more data. The trial aims to enroll 900 COPD patients across both the US and UK, in hopes of confirming the efficacy of vapendavir in alleviating respiratory symptoms.

Bridging Research and Reality

Altesa BioSciences operates with a clear mission: to drastically improve the lives of individuals affected by chronic lung diseases. The company stands at the frontline of scientific innovation through their commitment to tackling the root causes of exacerbations driven by viral infections.

With strategic investments and ongoing clinical trials, Altesa is not just advancing a drug; they are setting the groundwork for a paradigm shift in the management of chronic respiratory diseases. Their golden recognition at the Georgia Life Sciences Summit is more than just an honor—it underlines a future where treatments hold the potential to transform patient care.

For more information on Altesa BioSciences and its groundbreaking work, you can visit their official website at www.altesa.com.